Chronic hepatitis C (CHC) can lead to the development of liver cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). 1 Asia has the highest total HCV disease burden in the world with more than 50% of HCV-infected patients in the world living in Asia, and HCV genotype 1/1b (GT1/1b) is the most prevalent genotype and genotype subtype here. [1] [2] [3] Asian patients with GT1 have a higher sustained virological response (SVR) rates with interferon (IFN)-based therapy than non-Asians because they have higher prevalence of the favourable IL28B CC alleles. 4 With new IFN-free direct-acting antiviral (DAA) regimens, high efficacy and safety for patients with GT1 in phase 2-3 clinical studies have been shown worldwide including Asia. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, several special populations such as patients with advanced age, those with estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m 2 , HCC, those with significant comorbidities have generally been excluded or underrepresented in registration trials. A prior meta-analysis examining realworld outcomes of simeprevir (SMV)/sofosbuvir (SOF) AE ribavirin (RBV) regimen in patients with HCV GT1 infection in the USA found lower pooled SVR rates than those reported previously in randomised controlled trials. 16 Currently, real-world outcomes of DAA in Asia are limited with most studies not sufficiently large for robust analysis of various special populations, an important consideration in the evaluation of real-world cohort, which, unlike patients from protocoled clinical trials, is expected to be heterogeneous. The purpose of this systematic review and meta-analysis was to determine the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 3 insufficient data of SVR F I G U R E 1 Flow chart of the study screening and selection for inclusion in the meta-analysis. # Total number of patients is ≥ 15, but available SVR assessed in <15 patients in any DAA regimen; *Study focus only on IFN-free DAA experienced patient 2 | ME TH ODS
| Search strategy and selection criteria
This systematic review and meta-analysis was performed using a preplanned protocol (registered in PROSPERO: CRD42017067928). We searched PubMed and Embase for relevant studies published from inception through 31 May, 2017 without language restrictions. The search strategy used was ("ledipasvir" OR "sofosbuvir" OR "simeprevir" OR "daclatasvir" OR "asunaprevir" OR "ombitasvir" OR "dasabuvir") AND ("HCV" OR "hepatitis C"). We also manually searched the reference lists of included articles and relevant systematic reviews.
Two independent reviewers (FJ and BW) screened the titles and abstracts for eligibility using a pre-specified list of inclusion/exclusion criteria. Reports were included if they presented effectiveness of IFN-free DAA regimens for at least 8 weeks in adult HCV patients (age ≥ 18 years) in Asia. We included studies that presented SVR at 12 or 24 weeks after the end-of-treatment (SVR12/ 24, abbreviated as SVR below). We defined the real-world evidence based on Sherman and colleagues. 17 Eligible studies were post-marketing evaluation. We excluded pre-marketing phase clinical trials and studies that analysed patients who were enrolled in previous phase clinical trials. We also excluded studies that focused on patients with prior IFN-free DAAs experience, studies with insufficient data to calculate SVR in GT1-infected patients and studies with < 15 available patients with SVR outcomes in any DAA regimen arms as well as studies published only as abstracts. If there were more than one report from the same cohort, the most recent report or the report with the most complete data including subgroup data was selected for extraction. For studies with both SVR 12 and 24 outcomes, we extracted data for the former. The intention-to-treat analyses were favoured over modified intention-to-treat or per-protocol analyses for the studies that provided multiple values. If relevant data were not readily accessible, authors were contacted to obtain additional data for clarification. We also searched the Cochrane CENTRAL database using the same search term to identify additional eligible studies. We reported this systematic review and meta-analysis in accordance with the PRISMA statement. 19 
| Data extraction

| Quality assessment
The quality of included studies was rated using the Institute of Health Economics (IHE) quality appraisal checklist, which is usually employed for assessment of the quality of case series. As all of the included reports were single-arm studies, an assessment tool for case series is more suitable than the Newcastle-Ottawa scale (NOS).
In this 20-item checklist, both risk of bias and quality of reporting were scored by yes, no or partial/unclear answers. Studies with 0-2, 3-5, 6-8 and ≥ 9 "no" responses were considered as having low, moderate, high and very high risk of bias respectively.
| Statistical analysis
The primary outcome of this study was the pooled rate of SVR. We performed meta-analysis of proportion to compute the pooled estimates using a random-effect model (DerSimonian-Laird Method).
Given that, the SVR rate in many articles were 100% or close to 100%, we adopted Freeman-Turkey double arcsine transformation to transform the estimates. 95% confidence intervals (CI) were estimated using Wilson score method. Heterogeneity across the included studies was assessed using the Cochran Q-statistics and I 2 statistics, with I 2 statistics 25%-50%, 50%-75% and > 75% considered as mild, moderate and severe heterogeneity respectively. Small study bias was evaluated using the Egger's test and funnel plot. The threshold of statistical significance was set as P-value <0.05.
| Additional analyses
We performed subgroup analysis and meta-regression to explore the heterogeneity of the pooled SVR rate and to determine how the pre-planned variables affected the pooled estimates. In two studies, renal dysfunction was defined as eGFR < 60 mL/min/1.73 m 2 in the subgroup analysis.
( Figure 1 ). Of those, four studies were used only to extract data for subgroup analysis because the overall SVR data were already reported and extracted for overlapping populations in other four included studies. 22, 31, 35, 37 No additional studies were identified from the Cochrane database. All studies except two were published in English. 26, 43 In total, included studies represented data from eight countries and regions: Japan, China, Hong Kong, Korea, Iran, India, Pakistan and Myanmar. Data on study characteristics were shown in Table 1 .
Of the 41 studies included in this meta-analysis, 21 studies were considered as low risk of bias with a cumulative score ≤ 2. There were 17 and 3 studies considered as moderate (score 3-5) and high (score of 6-8) risk of bias (Table S1a) . (Table 1) . 61, 62 For the DCV/ASV group, the pooled SVR rate was 89.9% (95% CI 88.6- Figure S1, 3 ).
| Subgroups analysis for DCV/ASV regimen
Since the majority of the patients were treated with DCV/ASV or LDV/SOF AE RBV, further subgroups analysis was carried out to evaluate the effectiveness in special populations. There was insufficient sample size to do subgroup analysis with all other treatment regimens.
Subgroup analysis for SVR in patients treated with DCV/ASV was shown in Figure 2 ( Heterogeneity: I 2 = 0% P = 1.00
Heterogeneity: I 2 = 0.0%, P = 0.47 Heterogeneity: I 2 = 0%, P = 0.51 showed similar results as the overall GT1 cohort treated with this DAA regimen ( Figure 2 , Table S2 ).
| Subgroups analysis for LDV/SOF AE RBV regimen
Subgroup SVR analysis for patients treated with LDV/SOF AE RBV was shown in Figure 4 . Among GT1 patients dichotomised by the severity of liver fibrosis and RASs, there were 2.29% (95% CI -0.93- Regarding HCC patients treated with LDV/SOF AE RBV, those with prior history of HCC (n = 177) had a 6.02% (95% CI 1.46-11.19) lower likelihood to achieve SVR compared to those without HCC (n = 1365) (94.1%, 95% CI 89.9-97.3 vs 98.7%, 95% CI 97.5-99.6, P = 0.001) (Figure 4) . 50, 51, 54 Regarding subgroups by prior treatment status or age, SVR rates with LDV/SOF AE RBV were similar and above 97.5% for all subgroups ( Figure 4 , Table S3 ).
Regarding the subgroup of patients with renal dysfunction who were treated with LDV/SOF AE RBV, two studies included 71 patients with eGFR < 50 mL/min/ Only one of these studies included patients treated with RBV but the inclusion of RBV did not appear to affect SVR rates for overall population (Figure 4) . 52 Furthermore, the SVR rate of the 63 LDV/SOF cirrhotic patients who also received RBV was similar to the pooled SVR of the 508 cirrhotic patients who did not receive RBV (96.8%, 95% CI 90.7-99.9 vs 96.7%, 95% CI 94.1-98.6, P = 0.988).
50-52,54,55
Subgroup analysis of patients with the subtype 1b treated with LDV/SOF AE RBV showed similar results as those of the overall GT1 patients treated with the same regimen ( Figure 4 , Table S3 ).
Two studies evaluated DAA in patients who had undergone liver or kidney transplant achieved similar SVR as nontransplant patients (Table S4 ).
53,58
| Analysis of safety and adverse events
Pooled results of AEs for patients treated with DCV/ASV and patients treated with LDV/SOF AE RBV were summarised in Table 2 and 23, 27, 30, 32, 34, 36, 38, 41, [44] [45] [46] which was also the most common reason for early treatment discontinuation. Three patients died during the treatment but none was felt to be related with DCV/ASV treatment by the study authors. 40 For studies of LDV/SOF AE RBV-treated patients, 17.0% (95% CI 0.67-46.51) of patients experienced at least one AE, 53-55 but none for ALT elevation. 53, 55 The pooled estimate for rate of SAEs was 1.09% (95% CI 0-3.52). 51-55 All 14 (1%) of 1397 patients from six studies discontinued treatment early due to SAEs, 48,51-55 and two patients died from pneumonia after 4-week treatment and subarachnoid haemorrhage one day after end-of-treatment respectively. 51, 53 Of note, there were no differences in AEs or SAEs and premature treatment discontinuation in the subgroups by age and renal dysfunction with DCV/ASV treatment (Table S6, 7) .
| DISCUSSION
Our systematic review and meta-analysis showed that, except for a few subgroups, all oral DAA regimens for treatment of HCV GT1/1b T A B L E 2 Adverse events in HCV GT1-infected Asian patients treated with DCV/ASV and LDV/SOF AE RBV 67 However, the small sample size in the HCC patients treated with 3D+RBV regimen (n = 39) limits its conclusion. Therefore, more definitive data regarding HCC effect on SVR for DAA in general and for the specific DAA requires additional investigation.
Of interest, we found a higher pooled SVR rate among those with renal impairment, especially for patients with ESRD, compared to those without renal impairment for DCV/ASV regimen. Pharmacokinetic study has shown that the concentrations of DCV/ASV were lower in patients with renal failure but they also found higher SVR. 72 Thus, the reasons for the higher SVR observed in DCV/ASVtreated patients with renal impairment remains unclear.
Our study had several strengths. It is the largest meta-analysis done so far on SVR of DAA in genotype 1 patients in Asia, which represent the largest group of CHC patients in the world. 1, 3, 73 In total, we identified 41 studies from 37 separate cohorts including 8574 individuals, which allowed us to accurately estimate the pooled SVR rates of different DAA regimens, particularly among many special populations relevant to real-life practice. We also performed meta-regression to further determine how the pre-planned variables affected the pooled estimates. There were only mild to moderate heterogeneity among the included studies for most analyses.
Our study also has some limitations. Due to the distribution of HCV genotypes in Asia, HCV GT1 with subtype 1a is relatively uncommon; therefore, there were insufficient data for a meaningful pooled estimate for SVR for HCV GT1a, which is the predominant genotype in Western countries. Further studies are needed to clarify the effectiveness and tolerability of DAA regimens for HCV GT1a patients. As the vast majority of data were drawn from patients treated with DCV/ASV and LDV/SOF, our results were not generalisable for other DAA regimens. Most of the included studies were also from East Asia, especially Japan, due to genotype distribution and the accessibility of DAA; therefore, our data may not be generalisable for GT1 patients in all regions of Asia. Several important patient populations such as patients with decompensated liver disease, haemophilia and thalassaemia, co-infection with hepatitis B or human immunodeficiency viruses, children and pregnant patients
were not included in our study due to lack of primary data. Furthermore, subgroup data were extracted from different populations and different studies. Clinical heterogeneity is expected and this can compromise our subgroup analysis results, especially for real-world studies. Finally, the short follow-up period in most studies precluded definitive conclusions regarding the effect of HCV cure on the course of liver disease such as the risk of liver decompensation, HCC occurrence and/or recurrence, and survival. However, the primary objective of our study is to estimate pooled SVR rates for DAA therapy for HCV GT1 patients and not the long-term effect of SVR.
In conclusion, this is the first comprehensive systematic review and meta-analysis of real-world evidence of DAA for patients with chronic HCV GT1 infection in Asia. The overall cure rates and side effect profiles were excellent in real-world settings. Data on efficacy and factors associated with efficacy from pivotal phase 3 clinical trials and the current meta-analysis are summarised in Table 3 . Except for patients with baseline RASs treated with DCV/ASV and HCC patients treated with LDV/SOF, the difference in SVR rates between most subgroups were only modest, if any. Specifically, SVR rates were at least similar or higher in older patients and those with renal dysfunction and should not deter physicians from treating these populations if therapies are indicated otherwise. As the approval process of DAA becomes more accelerated and DAA therapy becomes more accessible to HCV-infected patients in Asia, 3, 73, 74 efforts should also be targeted at early screening, diagnosis and appropriate linkage to care for at risk patients as well as those with diagnosed infection, making HCV eradication a possibility and a reality in Asia.
